List of Excipients in Branded Drug TRALEMENT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
American Regent Inc	TRALEMENT	trace elements injection 4	0517-9305	WATER	2041-07-01

Tralement Excipient Strategy and Commercial Opportunities in Parenteral Nutrition

Last updated: August 4, 2026

Tralement is a four-trace-element injection used as a component of parenteral nutrition for adults and pediatric patients weighing at least 10 kg. Its commercial value is driven less by conventional excipient innovation than by sterile manufacturing, compatibility with nutrition admixtures, dosing convenience, supply reliability, and hospital-pharmacy workflow. The product contains zinc, copper, manganese, and selenium in an aqueous formulation adjusted to an acidic pH, with water for injection as the principal vehicle.[1]

What is Tralement and how is it used?

Tralement is a parenteral nutrition additive containing four essential trace elements:

Component	Elemental amount per mL
Zinc sulfate	Zinc 1 mg
Cupric sulfate	Copper 0.4 mg
Manganese sulfate	Manganese 0.1 mg
Selenious acid	Selenium 60 mcg

The labeled dose is generally 1 mL per day for patients weighing at least 10 kg, subject to clinical adjustment for age, disease state, renal or hepatic impairment, laboratory values, and the composition of the patient’s total parenteral nutrition regimen.[1]

Tralement is added to a parenteral nutrition solution before administration. It is not a standalone nutritional product and is not intended for direct intravenous injection without dilution.

What therapeutic category does Tralement occupy?

Tralement is a trace-element component of parenteral nutrition. Its primary institutional markets include:

• Intensive-care units
• Gastrointestinal failure programs
• Home-infusion providers
• Short-bowel syndrome treatment
• Oncology and transplant centers
• Neonatal and pediatric nutrition services, where the patient meets the labeled weight threshold
• Hospital pharmacies preparing compounded parenteral nutrition

The product competes with individual trace-element injections, alternative multi-element products, pharmacy-compounded combinations, and hospital-specific nutrition protocols.

What excipients are used in Tralement?

The formulation is intentionally simple. The principal non-active formulation component is water for injection. Hydrochloric acid is used to adjust the solution pH. The label identifies the product as a sterile, clear solution and does not identify an antimicrobial preservative.[1]

Formulation attribute	Tralement strategy
Vehicle	Water for injection
pH control	Hydrochloric acid
Preservative	No preservative identified in the prescribing information
Dosage form	Sterile injectable solution
Administration	Dilution into parenteral nutrition
Container	Single-dose sterile container
Primary formulation goal	Chemical stability and compatibility with PN admixtures

The low-excipient design limits the risk of excipient-related toxicity and reduces the number of variables introduced into complex parenteral nutrition formulations. It also simplifies regulatory characterization because the product does not rely on a novel solubilizer, surfactant, lipid vehicle, or polymeric delivery system.

Why is water for injection commercially important?

Water for injection is not a differentiating excipient, but it is critical to product quality. Trace metals can interact with container surfaces, formulation impurities, or other components of parenteral nutrition solutions. Control of particulate matter, elemental impurities, microbial contamination, and endotoxin burden is central to commercial performance.

A supplier with reliable sterile-water and aseptic-fill capacity can reduce manufacturing interruptions. That advantage matters in parenteral nutrition, where hospital pharmacies and home-infusion providers require predictable replenishment and cannot readily substitute products without reviewing concentration, container size, and compatibility.

Why does pH control matter?

The acidic pH supports chemical stability of the trace-element salts. The formulation must also remain suitable for dilution into a broader parenteral nutrition mixture containing amino acids, dextrose, electrolytes, vitamins, and, in some cases, lipid emulsion.

pH adjustment is therefore a functional formulation tool rather than a cosmetic attribute. A commercial improvement would need to preserve elemental stability while minimizing precipitation, adsorption, discoloration, and incompatibility after addition to the final nutrition solution.

What formulation patents protect Tralement?

Public FDA prescribing information for Tralement does not identify a formulation patent number or an Orange Book-listed patent in the product labeling.[1] The product’s defensibility is therefore more likely to depend on regulatory approval, sterile manufacturing controls, product-specific specifications, supply contracts, and know-how than on a visible composition-of-matter patent.

Potentially protectable technical areas include:

• Concentration ranges for the four trace elements
• pH-controlled aqueous formulations
• Stability in parenteral nutrition admixtures
• Container-closure systems
• Low-particulate sterile filling
• Manufacturing controls for metal contamination
• Compatibility with amino-acid and dextrose solutions
• Packaging that protects against light or adsorption
• Standardized pharmacy preparation procedures

These areas may be protected through patents, regulatory dossiers, confidential manufacturing processes, or a combination of the three. A patent search should distinguish product-specific claims from older patents covering trace-element mixtures generally.

How strong is the patent estate for Tralement?

The apparent patent strength is limited if assessed solely through publicly identified product patents. The more relevant commercial barriers are:

1. FDA approval for a sterile combination product.
2. Validation of the manufacturing process.
3. Demonstrated stability and compatibility.
4. Reliable access to pharmaceutical-grade trace-element raw materials.
5. Hospital and home-infusion formulary adoption.
6. Customer confidence in supply continuity.

This creates a moderate regulatory and manufacturing barrier but a potentially weak exclusivity position if competing manufacturers can develop and obtain approval for equivalent four-element products.

What is the FDA regulatory status of Tralement?

Tralement is an FDA-approved prescription injectable product for use in parenteral nutrition. The approved population is adults and pediatric patients weighing at least 10 kg.[1]

Key regulatory characteristics include:

Regulatory issue	Commercial effect
Sterile injectable product	High manufacturing and quality burden
Multi-ingredient trace-element formulation	Requires control of each elemental component
PN additive	Compatibility and stability data are commercially important
Pediatric weight limitation	Leaves an addressable market below 10 kg
Single-dose use	Increases packaging and unit-volume requirements
No novel delivery technology	Limits differentiation based on drug delivery

The weight threshold is strategically important. Infants and small children may require individualized trace-element dosing and products specifically designed for lower body weights. That segment creates a potential development opportunity but also requires pediatric dosing, safety, and compatibility work.

When does Tralement lose exclusivity?

A conventional small-molecule patent-expiration analysis is not sufficient for Tralement because the product’s public labeling does not identify a clear patent-based exclusivity date. Market entry will depend on the approved regulatory pathway and any applicable unlisted patents, regulatory exclusivity, contractual restrictions, or manufacturing constraints.

The relevant commercial timeline is:

Event	Significance
FDA approval	Established the approved four-element product
Patent listing, if any	Would define potential Orange Book litigation exposure
Regulatory exclusivity, if any	Could delay competing approval
Competitor approval	Determines practical substitution risk
Hospital conversion	Determines actual revenue erosion
Supply disruption	Can accelerate substitution or protect incumbent share

A competitor could challenge the market without creating immediate litigation if it develops an independently approved product. Conversely, a product with no significant patent protection can retain market share through availability, contracting, and pharmacy familiarity.

Are Paragraph IV challenges likely?

A Paragraph IV challenge would be relevant only if an applicable patent is listed in the FDA Orange Book for the reference product. No Paragraph IV dispute should be inferred from the existence of a competitive product or an abbreviated application alone.

For Tralement, the more plausible competitive routes are:

• Approval of another trace-element combination
• Development of individual-element substitutes
• Hospital pharmacy compounding
• Contract-manufacturing arrangements
• Product switching after shortages
• A regulatory application that does not rely on a listed patent claim

The commercial impact of a competitor would depend on whether hospitals treat the product as substitutable at the same concentration and whether pharmacy protocols require reformulation.

What generic entry risks exist for Tralement?

Generic or equivalent-product risk is moderate. The active ingredients are established mineral salts, and the product does not use a complex delivery system. That makes the pharmacological concept relatively accessible.

The barriers are higher at the manufacturing level:

• Aseptic processing
• Elemental assay accuracy
• Control of trace-metal impurities
• Container compatibility
• Stability after dilution
• Particulate and endotoxin control
• Batch-to-batch consistency
• Demonstration of appropriate product quality

The principal risk is not necessarily an immediate low-price generic launch. It is gradual erosion through alternative products that hospitals can incorporate into standardized PN order sets.

What generic launch scenarios are most plausible?

Scenario	Likely commercial effect
Direct four-element competitor with matching concentration	Highest substitution risk
Four-element product with different concentrations	Moderate risk; requires protocol changes
Individual-element products	Moderate risk in customized PN
Lower-cost hospital-compounded mixture	High operational burden but possible cost pressure
Pediatric product for patients below 10 kg	Segment expansion rather than direct substitution
Ready-to-use PN containing trace elements	Workflow competition; may reduce standalone additive demand

What excipient strategy could improve Tralement?

The strongest opportunities are incremental and operational rather than radical.

Lower-volume dosing

A more concentrated formulation could reduce the volume added to PN solutions. This may be useful when nutrition bags have limited volume, especially in fluid-restricted patients. The technical challenge is maintaining solubility, chemical stability, acceptable osmolality, and compatibility with the final admixture.

Improved container closure

A low-adsorption container system could reduce elemental loss during storage. Potential options include:

• Treated glass
• Low-extractable elastomer closures
• Polymer containers with validated metal compatibility
• Light-protective secondary packaging

Any new container would require extractables and leachables work, particulate testing, closure-integrity studies, and stability data.

Ready-to-use pharmacy presentation

A multi-dose institutional format could reduce repetitive manipulations, but preservatives and in-use stability would create additional regulatory and safety issues. A more practical strategy is a larger single-use vial or a pharmacy-friendly presentation with clear withdrawal instructions and validated in-use handling.

Compatibility-focused labeling

A commercially valuable improvement could be a stronger compatibility package showing performance in representative PN formulations. Data across amino-acid concentrations, dextrose levels, calcium and phosphate conditions, lipid emulsions, storage temperatures, and administration windows could support formulary adoption.

What commercial opportunities exist for Tralement?

Hospital pharmacy contracts

Hospitals value predictable supply, standardized dosing, and reduced preparation steps. A supplier can compete through:

• National group purchasing organization contracts
• Health-system conversion programs
• Automatic replenishment
• Emergency inventory commitments
• Electronic pharmacy-system integration
• Standardized PN order-set support

Price alone is unlikely to determine procurement. Shortages of injectable nutrition components can cause rapid shifts in purchasing behavior.

Home infusion

Home-infusion providers require products with reliable packaging, long shelf life, simple storage, and consistent availability. A supplier that supports recurring delivery and reduces compounding complexity can capture share even without a novel formulation.

Pediatric expansion

The labeled threshold of 10 kg leaves an opportunity for a lower-dose product designed for smaller children. A pediatric product could use:

• Lower concentrations
• Smaller vial sizes
• More precise dosing increments
• Compatibility data for neonatal and pediatric PN
• Packaging designed for low-volume withdrawals

This would be a separate regulatory and clinical development program, not a simple labeling extension.

Premixed parenteral nutrition

Premixed PN products containing trace elements can compete with standalone Tralement by reducing pharmacy labor. The opportunity is strongest where hospitals prioritize ready-to-use products and have limited compounding capacity.

A supplier could pursue co-formulation or co-packaging arrangements with PN manufacturers. The main technical barrier is stability across the full PN matrix, particularly when calcium, phosphate, vitamins, and lipid components are present.

Global markets

Geographic expansion requires attention to:

• National trace-element dosing guidelines
• Different PN compounding practices
• Local registration requirements
• Hospital procurement structures
• Raw-material qualification
• Regional packaging and language requirements
• Availability of individual trace-element alternatives

The core formulation may be transferable, but regulatory submissions must address country-specific PN standards and pediatric use.

How does Tralement compare with individual trace-element products?

Attribute	Tralement	Individual trace-element injections
Number of elements	Four	One
Pharmacy workflow	Simplified	More withdrawals and calculations
Customization	Lower	Higher
Risk of dosing error	Reduced for standard four-element supplementation	Higher when multiple products are combined
Pediatric flexibility	Limited by labeled weight and fixed ratios	Greater
Formulation complexity	Moderate	Lower per product
Contracting value	Strong for standardized PN	Useful for individualized regimens
Substitution risk	Alternative combinations	Multiple-source competition

Tralement is strongest where patients need the standard four-element combination and pharmacy systems favor a single additive. Individual products remain important when renal impairment, cholestasis, contamination concerns, or laboratory abnormalities require selective adjustment.

What litigation and settlement issues affect Tralement?

No major publicly identified patent litigation or Paragraph IV settlement should be attributed to Tralement without a verified case record. The relevant legal exposure is more likely to involve:

• Product liability
• Sterility failures
• Particulate contamination
• Labeling and dosing disputes
• Supply contracts
• Hospital purchasing agreements
• Manufacturing deviations
• Trade-secret protection for sterile production and compatibility data

Any future patent dispute would likely focus on formulation ranges, stability, compatibility, or manufacturing claims rather than the underlying trace elements, which are established substances.

How much revenue exposure exists?

Revenue exposure depends on the size of the standalone trace-element market, the proportion of PN patients receiving a standardized four-element combination, contract penetration, and the availability of substitutes. The product is exposed to price competition because the active ingredients are inexpensive relative to the cost of sterile manufacturing and distribution.

The principal revenue drivers are:

• Unit volume through hospital contracts
• Home-infusion demand
• Product availability during shortages
• Average selling price
• Conversion from individual products
• Pediatric and adult label coverage
• Manufacturing capacity
• Customer switching costs

The most valuable commercial asset may be supply reliability. In hospital nutrition markets, an available product can retain or gain share when competing products are constrained.

Key Takeaways

• Tralement is a four-trace-element injectable for parenteral nutrition in patients weighing at least 10 kg.
• Its formulation uses water for injection and pH adjustment with hydrochloric acid; no preservative is identified in the prescribing information.
• The product has limited apparent differentiation from an excipient perspective.
• Commercial protection is more likely to come from sterile manufacturing, compatibility data, supply reliability, and hospital contracts than from an easily visible patent estate.
• The main generic risk is entry by another four-element product or by lower-cost alternatives that fit hospital PN protocols.
• A concentrated formulation, pediatric presentation, improved container system, or compatibility-focused product package could create commercial differentiation.
• The largest unaddressed opportunity is a lower-dose pediatric formulation for patients below the current 10 kg threshold.
• Paragraph IV and Orange Book risk should be assessed against verified FDA patent listings rather than inferred from the product’s existence.

FAQs About Tralement Excipient and Commercial Strategy

Does Tralement contain preservatives?

The FDA prescribing information does not identify an antimicrobial preservative. Tralement is supplied as a sterile product for single-dose use.[1]

Can Tralement be injected directly into a patient?

No. It is intended to be added to a parenteral nutrition solution and administered after dilution according to the product labeling and institutional procedures.[1]

Is Tralement suitable for neonates?

The labeled indication covers adults and pediatric patients weighing at least 10 kg. Smaller patients require a product and dosing approach appropriate for their clinical and weight category.

Could a lower-volume Tralement formulation be commercially valuable?

Yes. A concentrated formulation could reduce the volume added to PN, but it would require new stability, compatibility, solubility, osmolality, container, and regulatory support.

What is the strongest competitive advantage for a Tralement supplier?

Reliable supply combined with validated compatibility, hospital-contract coverage, and pharmacy-friendly packaging is likely more valuable than conventional excipient novelty.

References

1. U.S. Food and Drug Administration. (2023). Tralement (trace elements injection 4) prescribing information*. Fresenius Kabi USA, LLC.

2. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/